Blog

News

404

PRISM BioLab raised 1.3 billion yen in Series C funding
Commentary on Protein-Protein and Protein-Peptide Interactions, peptidomimetics and related topics in drug discovery.

Notice of Our Merger

PRISM Pharma Co.,Ltd. (“Pharma”) and its wholly owned subsidiary, PRISM BioLab Co.,Ltd.(“BioLab”), have merged as of Octorber 1,2018. BioLab succeeds all Pharma’s rights and obligations. Because those two companies were operated as one by the same management, actual business will not change at all after this merger. PRISM BioLab Co., Ltd. President & CEO Dai...

Scroll to top
en_USEnglish